Vaxcyte closes $1.15 billion stock, warrant and convertible note offerings

Vaxcyte closed $1.15 billion in concurrent offerings of common stock, pre-funded warrants and 1.50% convertible senior notes due 2032, including full exercise of underwriter over-allotments. Net proceeds will fund VAX-31 clinical programs, manufacturing scale-up, commercial launch preparations, and general corporate purposes.